The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)

Abstract

Both etanercept regimens were efficacious in moderate-to-severe psoriasis, although the BIW/QW regimen consistently provided higher response rates than the QW/QW regimen. More potent topical medications were used electively in <25% of subjects in each group.

Efficacy and cost of etanercept in long-term psoriasis: Rational use in clinical practice

“…This posology saves costs while maintaining efficacy. Although efficacy is greater in patients who do the induction cycle with the dose of 50 mg twice weekly, the improvement in the PASI is only 11% different with regard to those who use half the dose in the first 24 weeks, as asserted by Strohal et al in the Pristine study (70.7% versus 81.3%, p50.05, for the groups with and without induction at the beginning, respectively) (15).…”

The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis

“…1): screening, treatment period 1 (weeks 0-12), treatment period 2 (weeks [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] and an extension phase (weeks 31-52). In treatment period 1, patients were randomized 1 : 1 to self-administer 50 mg GP2015 or 50 mg ETN (Enbrel â ; Amgen Inc., Thousand Oaks, CA, U.S.A.; European Union authorized) twice weekly, subcutaneously.…”

Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate‐to‐severe psoriasis: results from the PRISTINE trial

“…The Medical Outcomes Study (MOS)‐Sleep questionnaire and health‐related QoL measures were administered at baseline and weeks 12 and 24. Efficacy and safety evaluations have been previously described …”